~~<i id='71A901A46D'><strike id='71A901A46D'><tt id='71A901A46D'><pre id='71A901A46D'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：comprehensive 2025-09-29 16:40:26 Page View：78982

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novo Nordisk touts Wegovy study, but still struggling with supply
Next article： The high cost of giving birth even with insurance

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Timeline: How the deadly wildfires took over Maui day by day

5:04InthisimageobtainedfromtheCountyofMauiinHawaii,showsawildfireinLahaina,onAug.9,2023.Hawaiiwildfi

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

In same hospitals, Black patients receive fewer opioids than white patients

AdobeInequitiesinhealthcarearepervasive,fromaccesstoqualityofcare,andanewstudyfindsthatcommonopioids